Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$20.9M
+41.9% from 2023
Prescriptions
341
$61,350.15 per claim
Patients
40
42 prescribers
Total spending, 2024
$20.9M
$523,010.02 per patient
Medicare prescription drug plans paid $20.9M for Givlaari in 2024, for 341 prescriptions and refills to 40 patients (up 41.9% from 2023). The average cost per claim was $61,350.15.
Florida had the highest Medicare cost for Givlaari in 2024: $3.3M for 46 claims, followed by Missouri ($2.7M).
Syed M Karim, internal medicine in Belton, MO, had the highest Medicare cost for Givlaari in 2024: 17 claims costing $1.5M.
Givlaari is made by Alnylam Pharmaceuticals, Inc. (ALNY), listed in the Medicare spending data as Alnylam Pharmac.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Syed M Karim Belton, MO | Internal Medicine | 17 | Under 11 | $1.5M |
| Barry J Bacon Colville, WA | Family Practice | 14 | Under 11 | $1.2M |
| Robert Tassan Westwood, NJ |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 33 | 213 | 33 | $11.3M |
| 2023 | 38 | 254 | 37 | $14.7M |
| 2024 | 42 | 341 | 40 | $20.9M |
Spending by manufacturer as listed in the spending data
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Hematology-Oncology |
| 13 |
| Under 11 |
| $1.0M |
| Steven Siegel Middleburg, FL | Hematology-Oncology | 12 | Under 11 | $1.0M |
| Michael J McCleod Fort Myers, FL | Hematology-Oncology | 11 | Under 11 | $905K |
| Jorge G Otoya Kissimmee, FL | Medical Oncology | 11 | Under 11 | $851K |
| Alfredo E Torres Gonzalez Port Jefferson Station, NY | Hematology-Oncology | 12 | Under 11 | $640K |
| Alan E Lichtin Cleveland, OH | Hematology-Oncology | 13 | Under 11 | $555K |
| David N Oubre Hammond, LA | Hematology-Oncology | 13 | Under 11 | $552K |
| Eduardo A Garcia Lake Worth, FL | Hematology-Oncology | 12 | Under 11 | $514K |
| Ruben W Rhoades Philadelphia, PA | Hematology | 12 | Under 11 | $511K |
| Markus C Grompe Portland, OR | Medical Genetics and Genomics | 12 | Under 11 | $475K |
| Omayra Reyes Santiago Cayey, PR | Hematology-Oncology | 11 | Under 11 | $467K |
| John D Northup Savannah, GA | Gastroenterology | 11 | Under 11 | $452K |
| Olusola Ogundipe Valparaiso, IN | Hematology-Oncology | 11 | Under 11 | $452K |
| Isam A Abdel-Karim Fort Smith, AR | Hematology-Oncology | 11 | Under 11 | $441K |
| Manufacturer | Claims | Spending |
|---|---|---|
| Alnylam Pharmac ALNY | 341 | $20.9M |